{"id":"NCT02572817","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","briefTitle":"Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A","officialTitle":"A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2018-04-26","completion":"2018-05-18","firstPosted":"2015-10-09","resultsPosted":"2019-06-14","lastUpdate":"2019-06-25"},"enrollment":138,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza A Virus Infection"],"interventions":[{"type":"BIOLOGICAL","name":"High-titer anti-influenza plasma","otherNames":[]},{"type":"BIOLOGICAL","name":"Low-titer anti-influenza plasma","otherNames":[]}],"arms":[{"label":"High-titer anti-influenza plasma","type":"EXPERIMENTAL"},{"label":"Low-titer anti-influenza plasma","type":"ACTIVE_COMPARATOR"}],"summary":"This study assessed the efficacy and safety of anti-influenza immune plasma, as an addition to standard of care antivirals, in participants hospitalized with severe influenza A infection.","primaryOutcome":{"measure":"Clinical Status at Day 7","timeFrame":"Day 7","effectByArm":[{"arm":"High-titer Anti-influenza Plasma mITT","deltaMin":2,"sd":null},{"arm":"Low-titer Anti-influenza Plasma mITT","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.54"}]},"eligibility":{"minAge":"2 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":1},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["9824069","8844239","16546531","12885479","23295778","22379384","31582360"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":91},"commonTop":[]}}